Co-Diagnostics, the molecular diagnostics company known for its patented Co-Dx PCR platform, has secured a major intellectual property victory: its first patent in Australia for PCR platform.

 

The patent, initially filed in May 2022 and granted in June 2025, is the first for the new Co-Dx PCR platform and offers broad protection in Australia for the company’s proprietary system and methods for nucleic acid detection and analysis. 

 

It specifically covers the design and operation of the Co-Dx PCR Pro instrument and test cups, including its ability to perform high-quality PCR testing outside traditional laboratory settings.

 

“This patent represents another significant milestone in securing global protection for our technology as we continue expanding the potential applications of the point-of-care PCR platform,” said Dwight Egan, CEO of Co-Dx. 

 

“From the beginning, Co-Dx's goal has been to make accurate, accessible PCR testing available where it is needed most, and strengthening our global IP portfolio is essential to that mission.”

 

The patent also positions Co-Dx strategically in a region where the company and potential partners may introduce or distribute the Co-Dx PCR platform. 

 

Australia recently faced a record-breaking flu season, and the patent coverage safeguards the commercial potential of tests like the Co-Dx PCR Flu A/B, COVID, RSV multiplex assay, which is currently undergoing clinical performance testing.

 

The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments. Leveraging Co-Diagnostics’ patented Co-Primers technology, the system aims to provide rapid, sensitive, and specific molecular diagnostics across a wide range of infectious diseases.